These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19995961)

  • 41. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Approaches for the development of antiviral compounds: the case of hepatitis C virus.
    Schinazi RF; Coats SJ; Bassit LC; Lennerstrand J; Nettles JH; Hurwitz SJ
    Handb Exp Pharmacol; 2009; (189):25-51. PubMed ID: 19048196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action.
    Windisch MP; Jo S; Kim HY; Kim SH; Kim K; Kong S; Jeong H; Ahn S; No Z; Hwang JY
    Eur J Med Chem; 2014 May; 78():35-42. PubMed ID: 24675178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of novel treatments for hepatitis C.
    Webster DP; Klenerman P; Collier J; Jeffery KJ
    Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Animal model for hepatitis C virus infection].
    Tsukiyama-Kohara K; Kohara M
    Uirusu; 2015; 65(2):255-262. PubMed ID: 27760924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.
    He S; Li K; Lin B; Hu Z; Xiao J; Hu X; Wang AQ; Xu X; Ferrer M; Southall N; Zheng W; Aubé J; Schoenen FJ; Marugan JJ; Liang TJ; Frankowski KJ
    J Med Chem; 2017 Jul; 60(14):6364-6383. PubMed ID: 28636348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.
    Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP
    Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of efficacious pangenotypic hepatitis C virus therapies.
    Ashraf MU; Iman K; Khalid MF; Salman HM; Shafi T; Rafi M; Javaid N; Hussain R; Ahmad F; Shahzad-Ul-Hussan S; Mirza S; Shafiq M; Afzal S; Hamera S; Anwar S; Qazi R; Idrees M; Qureshi SA; Chaudhary SU
    Med Res Rev; 2019 May; 39(3):1091-1136. PubMed ID: 30506705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System.
    Nakajima S; Watashi K; Ohashi H; Kamisuki S; Izaguirre-Carbonell J; Kwon AT; Suzuki H; Kataoka M; Tsukuda S; Okada M; Moi ML; Takeuchi T; Arita M; Suzuki R; Aizaki H; Kato T; Suzuki T; Hasegawa H; Takasaki T; Sugawara F; Wakita T
    J Virol; 2016 Oct; 90(20):9058-74. PubMed ID: 27489280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemical genetics-based development of small molecules targeting hepatitis C virus.
    Jin G; Lee J; Lee K
    Arch Pharm Res; 2017 Sep; 40(9):1021-1036. PubMed ID: 28856597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Shape-based virtual screening, synthesis and evaluation of novel pyrrolone derivatives as antiviral agents against HCV.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Brancale A
    Bioorg Med Chem Lett; 2017 Feb; 27(4):936-940. PubMed ID: 28089348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HCV drug discovery aimed at viral eradication.
    Schinazi RF; Bassit L; Gavegnano C
    J Viral Hepat; 2010 Feb; 17(2):77-90. PubMed ID: 20040045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
    Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation and application of natural products for viral infections].
    Hayashi K; Hayashi T; Lee JB
    Yakugaku Zasshi; 2010 Feb; 130(2):171-6. PubMed ID: 20118639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.
    Huang P; Goff DA; Huang Q; Martinez A; Xu X; Crowder S; Issakani SD; Anderson E; Sheng N; Achacoso P; Yen A; Kinsella T; Darwish IS; Kolluri R; Hong H; Qu K; Stauffer E; Goldstein E; Singh R; Payan DG; Lu HH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1419-29. PubMed ID: 18227176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Visualizing the Essential Role of Complete Virion Assembly Machinery in Efficient Hepatitis C Virus Cell-to-Cell Transmission by a Viral Infection-Activated Split-Intein-Mediated Reporter System.
    Zhao F; Zhao T; Deng L; Lv D; Zhang X; Pan X; Xu J; Long G
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27852847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.